First subject dosed in Amylyx’s Phase I trial of ALS therapy

Submitted by admin on April 10, 2025 - 11:49am

Source:

Clinical Trials Arena

News Tags:

Amylyx Pharmaceuticals

AMX0114

ALS

clinical trials

Headline:

First subject dosed in Amylyx’s Phase I trial of ALS therapy

snippet:

Amylyx Pharmaceuticals has dosed the first subject in the randomised Phase I LUMINA trial, investigating AMX0114, a potential treatment for amyotrophic lateral sclerosis (ALS).

Search form

You are here

First subject dosed in Amylyx’s Phase I trial of ALS therapy

First subject dosed in Amylyx’s Phase I trial of ALS therapy